Genedrive PLC Genedrive confirms receipt of India Import License (1975D)
June 25 2021 - 7:17AM
UK Regulatory
TIDMGDR
RNS Number : 1975D
Genedrive PLC
25 June 2021
genedrive plc
("genedrive" or the "Company")
Genedrive confirms receipt of India Import License
genedrive plc (AIM: GDR), the near patient molecular diagnostics
company, notes the recent rise in its share price and confirms that
it has received a license to import the Genedrive(R) SARS-CoV-2 Kit
into India via its partner DIVOC Health. This step follows the
approval of the product at the Indian Centre for Medical Research
on 30 April 2021.
As previously stated, India has introduced pricing controls in
their routine public testing market that favours the provision of
lower cost/basic tests than the Genedrive SARS-Cov-2 Kit. The
Company continues to assess specific commercial opportunities with
DIVOC Health in the Indian public and private markets.
For further details please contact:
genedrive plc +44 (0)161 989 0245
David Budd: CEO / Matthew Fowler:
CFO
Peel Hunt LLP (Nominated Adviser
and Joint Broker) +44 (0)20 7418 8900
James Steel / Victoria Erskine
finnCap (Joint Broker) +44 (0)20 7220 0500
Geoff Nash / Kate Bannatyne / Alice
Lane
Walbrook PR Ltd (Media & Investor +44 (0)20 7933 8780 or genedrive@walbrookpr.com
Relations)
+44 (0)7980 541 893 / +44 (0)7876
Paul McManus / Anna Dunphy 741 001
About genedrive plc ( http://www.genedriveplc.com )
genedrive plc is a molecular diagnostics company developing and
commercialising a low cost, rapid, versatile, simple to use and
robust point of need molecular diagnostics platform for the
diagnosis of infectious diseases and for use in patient
stratification (genotyping), pathogen detection and other
indications. The Company has assays on market for the detection of
HCV, certain military biological targets, and has tests in
development for tuberculosis (mTB). The Company recently released a
high throughput SARS-CoV-2 assay and has in development a
Genedrive(R) Point of Care version of the assay, both based on
Genedrive(R) chemistry.
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
MSCSEIFEIEFSEFM
(END) Dow Jones Newswires
June 25, 2021 08:17 ET (12:17 GMT)
Genedrive (LSE:GDR)
Historical Stock Chart
From Mar 2024 to Apr 2024
Genedrive (LSE:GDR)
Historical Stock Chart
From Apr 2023 to Apr 2024